Bank of New York Mellon
ELVN icon

Bank of New York Mellon’s Enliven Therapeutics ELVN Stock Holding History

Bank of New York Mellon’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.03M Sell
118,853
-1,204
-1% -$51.1K ﹤0.01% 2328
2026
Q1 		$4.71M Buy
120,057
+9,488
+9% +$263K ﹤0.01% 2345
2025
Q4 		$1.7M Sell
110,569
-5,047
-4% -$101K ﹤0.01% 2936
2025
Q3 		$2.37M Buy
115,616
+17,487
+18% +$353K ﹤0.01% 2713
2025
Q2 		$1.97M Buy
98,129
+4,562
+5% +$86.4K ﹤0.01% 2761
2025
Q1 		$1.84M Buy
93,567
+3,992
+4% +$85.9K ﹤0.01% 2734
2024
Q4 		$2.02M Sell
89,575
-828
-0.9% -$21.5K ﹤0.01% 2761
2024
Q3 		$2.31M Sell
90,403
-23,706
-21% -$549K ﹤0.01% 2683
2024
Q2 		$2.67M Buy
114,109
+37,632
+49% +$792K ﹤0.01% 2639
2024
Q1 		$1.35M Sell
76,477
-3,652
-5% -$56K ﹤0.01% 2990
2023
Q4 		$1.11M Sell
80,129
-630
-0.8% -$7.71K ﹤0.01% 3131
2023
Q3 		$1.1M Sell
80,759
-165
-0.2% -$2.78K ﹤0.01% 3097
2023
Q2 		$1.65M Buy
80,924
+65,629
+429% +$1.33M ﹤0.01% 2941
2023
Q1 		$335K Buy
15,295
+2,288
+18% +$46.5K ﹤0.01% 3694
2022
Q4 		$213K Sell
13,007
-98
-0.7% -$1.57K ﹤0.01% 3948
2022
Q3 		$120K Hold
13,105
– – ﹤0.01% 4163
2022
Q2 		$64K Sell
13,105
-4,318
-25% -$21.1K ﹤0.01% 4309
2022
Q1 		$131K Buy
17,423
+12,758
+273% +$84.1K ﹤0.01% 4347
2021
Q4 		$42K Hold
4,665
– – ﹤0.01% 4517
2021
Q3 		$76K Buy
+4,665
New +$96.9K ﹤0.01% 4380
2021
Q2 		– Sell
-4,537
Closed -$153K – 4413
2021
Q1 		$153K Sell
4,537
-2,043
-31% -$104K ﹤0.01% 4108
2020
Q4 		$580K Buy
6,580
+2,981
+83% +$250K ﹤0.01% 3544
2020
Q3 		$293K Sell
3,599
-207
-5% -$18.7K ﹤0.01% 3727
2020
Q2 		$421K Buy
+3,806
New +$426K ﹤0.01% 3560

Other funds holding ELVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Bank of New York Mellon's ELVN Position: Q2 2026 in Review

Bank of New York Mellon reduced its Enliven Therapeutics (ELVN) stake by 1% in Q2 2026, selling an estimated $51.1K and leaving 118,853 shares worth $6.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2328.

Bank of New York Mellon first reported a position in ELVN in Q2 2020 and has held it in 24 quarters since. 83 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Bank of New York Mellon held 118,853 shares of Enliven Therapeutics worth $6.03M as of Q2 2026.
  • Bank of New York Mellon sold 1,204 Enliven Therapeutics shares in Q2 2026, an estimated $51.1K.
  • Enliven Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2328 holding.
  • Bank of New York Mellon first reported a position in Enliven Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • 83 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.